Tesis Biosciences

Tesis Biosciences, established in 2019, operates in the healthcare sector, specializing in targeted genetic sequencing and high-complexity laboratory testing. The company was founded by Ronald King and Divyen Patel. The firm, originally known as Tesis Labs, rebranded in November 2021 to Tesis Biosciences to reflect its expanded focus beyond laboratory services to include advancing clinical research and diagnostics. A significant milestone was the acquisition of Genome Explorations in February 2022, which accelerated its capabilities in clinical research for chronic diseases.

The company's core business revolves around a genetically integrated medical platform used for advanced testing to address major chronic conditions like heart disease, cancer, diabetes, and Alzheimer's. Tesis Biosciences serves a diverse client base that includes physicians, hospitals, pharmaceutical companies, medical device companies, and accountable care organizations (ACOs). Its business model involves forming collaborative partnerships to provide these entities with the necessary tools and data for diagnostics, clinical trials, and personalized patient care. Revenue is generated by offering genetic testing services, providing access to its comprehensive genetic database to de-risk drug development, and supplying data and bioinformatics analysis to help partners design protocols for earlier diagnosis.

The primary service is providing customizable, high-complexity genetic testing panels. These panels are designed to identify changes in chromosomes, genes, or proteins, which helps in predicting specific chronic diseases. For pharmaceutical and medical device partners, Tesis offers access to its genetic data repository to accelerate product development and approval processes. For healthcare providers such as hospitals and physician groups, the company delivers testing expertise and technology that enables the creation of personalized care plans based on a patient's genetic profile. This is facilitated through a user-friendly interface and portals that provide 24/7 access to real-time results. The company also provides services for pharmacogenomics, which helps in determining a patient's response to a wide range of pharmaceuticals.

Keywords: genetic sequencing, clinical diagnostics, chronic disease management, personalized medicine, pharmacogenomics, next-generation sequencing, clinical research support, medical data analysis, bioinformatics, molecular testing, drug development support, medical device testing, accountable care organizations, physician partnerships, hospital laboratory services, genetic database, targeted genetic panels, cancer genomics, cardiovascular genetics, neurogenetics